These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21193423)

  • 1. ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.
    Perna F; Abdel-Wahab O; Levine RL; Jhanwar SC; Imada K; Nimer SD
    Haematologica; 2011 Feb; 96(2):342-3. PubMed ID: 21193423
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
    Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
    Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
    Mauro MJ
    Curr Treat Options Oncol; 2007 Aug; 8(4):287-95. PubMed ID: 18157514
    [No Abstract]   [Full Text] [Related]  

  • 4. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
    Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK
    Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
    Nowak D; Ogawa S; Müschen M; Kato M; Kawamata N; Meixel A; Nowak V; Kim HS; Kang S; Paquette R; Chang MS; Thoennissen NH; Mossner M; Hofmann WK; Kohlmann A; Weiss T; Haferlach T; Haferlach C; Koeffler HP
    Blood; 2010 Feb; 115(5):1049-53. PubMed ID: 19965645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Hwang YY; Tse E; So JC; Wan TS; Kwong YL
    Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 9. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.
    Godley LA
    Leuk Lymphoma; 2009 Jun; 50(6):871-2. PubMed ID: 19479615
    [No Abstract]   [Full Text] [Related]  

  • 11. Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.
    Press RD
    Oncologist; 2010; 15(7):744-9. PubMed ID: 20566700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil numerals.
    Bitar C; Saba N
    Blood; 2014 Mar; 123(11):1635. PubMed ID: 24761452
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ
    Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract]   [Full Text] [Related]  

  • 16. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case.
    Zeidan A; Kakati S; Anderson B; Barcos M; Wetzler M
    Cancer Genet Cytogenet; 2007 Jul; 176(2):169-71. PubMed ID: 17656263
    [No Abstract]   [Full Text] [Related]  

  • 17. Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia.
    Lu CM; Zhou L; Feng S; Kohn PH; Qi Z; Yu J
    Leuk Lymphoma; 2011 Nov; 52(11):2182-4. PubMed ID: 21718138
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.
    Kubota Y; Waki M
    Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400
    [No Abstract]   [Full Text] [Related]  

  • 19. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
    Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
    Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.